Patent application number | Description | Published |
20080242868 | PROCESS FOR PREPARING EPOTHILONE DERIVATIVES BY SELECTIVE CATALYTIC EPOXIDATION - The present invention describes a novel process for preparing an epothilone derivative using substituted pyridines and methyltrioxorhenium as catalyst. | 10-02-2008 |
20090297454 | Perfluoroalkyl-Containing Complexes, Process For Their Production As Well As Their Use - The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging. | 12-03-2009 |
20100248313 | NOVEL OPTICALLY ACTIVE, HETEROAROMATIC BETA-HYDROXY ESTERS AND PROCESSES FOR THEIR PREPARATION FROM BETA-KETO ESTERS AND PROCESSES FOR THE PREPARATION OF THESE BETA-KETO ESTERS - The present invention relates to new optically active heteroaromatic β-hydroxy esters useful in the synthesis of epothilone derivatives, to certain compounds used to produce these intermediates, as well as to processes for their production. | 09-30-2010 |
20120064002 | Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1- ,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents - Enantiomer-pure compounds of general formulas VIIa and VIIb | 03-15-2012 |
20120077984 | Process For Preparing Epothilone Derivatives By Selective Catalytic Epoxidation - The present invention describes a novel process for preparing an epothilone derivative using substituted pyridines and methyltrioxorhenium as catalyst. | 03-29-2012 |
20120309962 | PROCESS FOR THE PREPARATION OF CALCOBUTROL - The invention concerns a process for the preparation of the calcium complex of 0-(2,3-Dihydroxy-1-(hydroxymethyl)propyl)-1,4,7,10-tetraazacyclodecane-4,7-triacetic acid, also known as Calcobutrol, starting from the pure gadolinium complex (Gadobutrol). The invention furthermore concerns Calcobutrol with a hitherto unknown level of purity. | 12-06-2012 |
20130116429 | Gadobutrol Preparation in a One-Pot Process by means of DMF Acetal and N-Methylimidazole - A process is described for preparation of the gadolinium complex of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane “gadobutrol=Gadovist®” in a one-pot process by means of DMF acetal and N-methylimidazole. Gadovist is a gadolinium-containing contrast agent for nuclear spin tomography and has been approved since 2000 in Germany in the indication “contrast amplification in cranial and spinal magnetic resonance tomography”. | 05-09-2013 |
20130158241 | Process for Preparing Crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic Acid and Use for Production of Primovist.RTM. - The invention relates to a method for producing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)undecanedioic acid of the formula I | 06-20-2013 |
20140107325 | PREPARATION OF HIGH-PURITY GADOBUTROL - What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist®. | 04-17-2014 |